NO20000577L - Eprosartanarginyl-ladning-nøytraliseringskompleks og en fremgangsmåte for dets fremstilling og formulering - Google Patents

Eprosartanarginyl-ladning-nøytraliseringskompleks og en fremgangsmåte for dets fremstilling og formulering

Info

Publication number
NO20000577L
NO20000577L NO20000577A NO20000577A NO20000577L NO 20000577 L NO20000577 L NO 20000577L NO 20000577 A NO20000577 A NO 20000577A NO 20000577 A NO20000577 A NO 20000577A NO 20000577 L NO20000577 L NO 20000577L
Authority
NO
Norway
Prior art keywords
eprosartanarginyl
formulation
preparation
charge neutralization
neutralization complex
Prior art date
Application number
NO20000577A
Other languages
English (en)
Other versions
NO20000577D0 (no
NO317771B1 (no
Inventor
Manga R Gudipati
Gopadi M Venkatesh
Nageswara R Palepu
John M Jushcyshyn
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20000577D0 publication Critical patent/NO20000577D0/no
Publication of NO20000577L publication Critical patent/NO20000577L/no
Publication of NO317771B1 publication Critical patent/NO317771B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20000577A 1997-08-06 2000-02-04 Eprosartanarginyl-ladning-noytraliseringskompleks og en fremgangsmate for dets fremstilling og anvendelse derav NO317771B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5499097P 1997-08-06 1997-08-06
PCT/US1998/016245 WO1999007365A1 (en) 1997-08-06 1998-08-04 Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation

Publications (3)

Publication Number Publication Date
NO20000577D0 NO20000577D0 (no) 2000-02-04
NO20000577L true NO20000577L (no) 2000-02-29
NO317771B1 NO317771B1 (no) 2004-12-13

Family

ID=21994861

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000577A NO317771B1 (no) 1997-08-06 2000-02-04 Eprosartanarginyl-ladning-noytraliseringskompleks og en fremgangsmate for dets fremstilling og anvendelse derav

Country Status (27)

Country Link
EP (1) EP1027047B1 (no)
JP (1) JP4463975B2 (no)
KR (1) KR100508044B1 (no)
CN (1) CN1276724A (no)
AR (1) AR015930A1 (no)
AT (1) ATE341325T1 (no)
AU (1) AU739295B2 (no)
BR (1) BR9811926A (no)
CA (1) CA2299470C (no)
CO (1) CO4960666A1 (no)
CY (1) CY1105851T1 (no)
CZ (1) CZ296274B6 (no)
DE (1) DE69836095T2 (no)
DK (1) DK1027047T3 (no)
ES (1) ES2273433T3 (no)
HK (1) HK1031688A1 (no)
HU (1) HUP0201624A3 (no)
IL (1) IL134378A (no)
NO (1) NO317771B1 (no)
NZ (1) NZ502644A (no)
PL (1) PL198875B1 (no)
PT (1) PT1027047E (no)
SA (1) SA98190592B1 (no)
TR (1) TR200000350T2 (no)
TW (1) TW570921B (no)
WO (1) WO1999007365A1 (no)
ZA (1) ZA987018B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
EP1197223B1 (en) * 1999-04-28 2005-02-16 Takeda Pharmaceutical Company Limited Preventives / remedies / progression inhibitors for simplex retinopathy or preproliferating retinopathy
BRPI0406987A (pt) 2003-01-31 2006-01-10 Sankyo Co Medicamento para a prevenção e/ou tratamento de arteriosclerose, medicamentos para a inibição de proliferação de células do músculo liso vascular, de formação de neoìntima dos vasos sanguìneos e de remodelação vascular, medicamento para a prevenção de restenose que segue intervenção coronária percutânea, e, medicamentos para a profilaxia e/ou tratamento de hipertensão ou doenças causadas por hipertensão ou doenças causadas por hipertensão, de doenças cardìacas, de angina do peito, de infarto miocárdico, de arritmia, de morte súbita, de insuficiência cardìaca, de hipertrofia cardìaca, de doenças renais, de nefropatia diabética, de glomerulonefrite, de nefrosclerose, de doenças cerebrovasculares, de infarto cerebral, e de hemorragia cerebral
NO323391B1 (no) 2005-09-28 2007-04-23 Hts Hans Torgersen & Sonn As Barnepose
EP2167047A2 (en) * 2007-06-06 2010-03-31 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
JP5476782B2 (ja) * 2009-04-21 2014-04-23 大正製薬株式会社 アルギニン含有錠剤の製造方法
JP5446716B2 (ja) * 2009-10-21 2014-03-19 大正製薬株式会社 アルギニン及びカルニチン含有錠剤の製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
DE69131021T2 (de) * 1990-12-14 1999-08-12 Smithkline Beecham Corp Angiotensin-ii-rezeptor blockierende zusammensetzungen
JP3214856B2 (ja) * 1990-12-14 2001-10-02 スミスクライン・ビーチャム・コーポレイション イミダゾリル−アルケン酸
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
DE4208052A1 (de) * 1992-03-13 1993-09-16 Bayer Ag Imidazolyl substituierte phenylessigsaeureamide
FR2688781B1 (fr) * 1992-03-23 1994-07-01 Sanofi Elf Imidazolines n-substituees par un groupement biphenylmethyle, leur preparation, les compositions pharmaceutiques en contenant.
DE4210787A1 (de) * 1992-04-01 1993-10-07 Bayer Ag Cycloalkyl- und Heterocyclyl substituierte Imidazolylpropensäurederivate
JPH0841053A (ja) * 1994-07-28 1996-02-13 Nkk Corp ヘテロアリールアルキル基を有するピリミジン誘導体及 び該誘導体を有効成分として含有するアンジオテンシン ｉｉ拮抗剤
US5645839A (en) * 1995-06-07 1997-07-08 Trustees Of Boston University Combined use of angiotensin inhibitors and nitric oxide stimulators to treat fibrosis
WO1997021707A1 (en) * 1995-12-14 1997-06-19 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone

Also Published As

Publication number Publication date
EP1027047A4 (en) 2002-09-18
CZ296274B6 (cs) 2006-02-15
TR200000350T2 (tr) 2000-12-21
JP4463975B2 (ja) 2010-05-19
WO1999007365A1 (en) 1999-02-18
CY1105851T1 (el) 2011-02-02
EP1027047B1 (en) 2006-10-04
JP2001513498A (ja) 2001-09-04
IL134378A0 (en) 2001-04-30
AU739295B2 (en) 2001-10-11
BR9811926A (pt) 2000-08-22
NO20000577D0 (no) 2000-02-04
AU8768898A (en) 1999-03-01
CZ2000406A3 (cs) 2000-09-13
NO317771B1 (no) 2004-12-13
HUP0201624A2 (hu) 2002-12-28
ES2273433T3 (es) 2007-05-01
CA2299470C (en) 2010-01-26
NZ502644A (en) 2002-03-01
PL198875B1 (pl) 2008-07-31
DE69836095D1 (de) 2006-11-16
CO4960666A1 (es) 2000-09-25
HUP0201624A3 (en) 2003-03-28
CA2299470A1 (en) 1999-02-18
KR100508044B1 (ko) 2005-08-17
DE69836095T2 (de) 2007-04-12
ATE341325T1 (de) 2006-10-15
PT1027047E (pt) 2007-01-31
EP1027047A1 (en) 2000-08-16
AR015930A1 (es) 2001-05-30
HK1031688A1 (en) 2001-06-22
KR20010022582A (ko) 2001-03-26
TW570921B (en) 2004-01-11
DK1027047T3 (da) 2007-01-29
SA98190592B1 (ar) 2006-06-20
IL134378A (en) 2004-02-19
ZA987018B (en) 1999-02-08
PL341562A1 (en) 2001-04-23
CN1276724A (zh) 2000-12-13

Similar Documents

Publication Publication Date Title
EP0846088A4 (en) CEMENT FORMULATION
IL112521A0 (en) Pharmaceutical formulation
ZA965368B (en) A pharmaceutical formulation
ID24654A (id) Formulasi farmasi omeprazola
ZA982872B (en) Pharmaceutical formulation
ZA96124B (en) A pharmaceutical formulation
NO981008D0 (no) Farmasöytisk formulering
NO984503L (no) Eprosartandihydrat og en fremgangsmÕte for dets fremstilling og formulering
BR9607039A (pt) Acoplamento separável e ferramenta correspondente
ZA958606B (en) A pharmaceutical formulation
GB9405856D0 (en) Pharmaceutical formulation
NO20000577L (no) Eprosartanarginyl-ladning-nøytraliseringskompleks og en fremgangsmåte for dets fremstilling og formulering
ZA984872B (en) An improved brushing device and a process for manufacture thereof
EP0970065A4 (en) ANTIBIOTICS AND THEIR PREPARATION PROCESS
GB9523566D0 (en) Pharmaceutical formulation
PT939083E (pt) Complexos de ferro-succinilcaseina procedimento para sua preparacao e suas composicoes farmaceuticas
GB9709739D0 (en) Pharmaceutical formulation
ZA96526B (en) Novel pharmaceutical formulation
HUP0004510A3 (en) Process for obtaining l-dihydroorotic acid and use thereof
ZA964372B (en) A pharmaceutical formulation
EE200000401A (et) Farmatseutilise preparaadi valmistamismeetod
ZA965367B (en) A pharmaceutical formulation
NO176424C (no) Eksentrisk kjeveknuser
ZA96122B (en) A pharmaceutical formulation
ZA952017B (en) Veterinary formulation

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees